Radiotherapy alone or combined with chemotherapy for base of tongue squamous cell carcinoma

Christopherson, Kaitlin M.; Morris, Christopher G.; Kirwan, Jessica; Amdur, Robert J.; Dziegielewski, Peter T.; Boyce, Brian; Mendenhall, William M.

doi:10.1002/lary.26460

Cited by 6 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our current analysis, long-term retrospective analyses of patients with tonsil and base of tongue OPSCC have also been performed at our institution (Table 6). 22,23 A comparison across oropharyngeal disease sites demonstrates very similar 5-year CSS for patients with stage I-III disease. Patients with Stage IVA disease, however, had markedly worse 5-year CSS, particularly compared to base of tongue (BOT) patients.…”

Section: Discussionmentioning

confidence: 98%

Radiation treatment of soft palate squamous cell carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: To report our institution's experience treating soft palate squamous cell carcinoma with radiotherapy alone or combined with adjuvant chemotherapy and/or neck dissection for residual disease. Methods:We analyzed 159 patients treated curatively between 1963 and 2016. Median follow-up was 4 years. Results:The 5-year local control rates were T1, 90%; T2, 90%; T3, 70%; and T4, 59%. The 5-year cause-specific survival (CSS) rate was nearly identical for patients with stage I-III disease (88%, 86%, and 88%, respectively) compared to stage IVA/B (58%). Five-year overall survival was similar between patients with stage I-III disease (50%, 57%, and 54%, respectively) and approximately double that of patients with stage IVA/B disease (26%). Thirteen patients (8%) had severe complications related to radiotherapy. Conclusions:The likelihood of cure after definitive radiotherapy is relatively high in patients with stage I-III disease with soft palate carcinoma. Patients with stage IVA/B disease have a lower cure rate but with a 5-year CSS exceeding 50%. K E Y W O R D Sclinical outcomes, head and neck, radiation oncology, radiotherapy, surgery

show abstract

Section: Discussionmentioning

confidence: 98%

Radiation treatment of soft palate squamous cell carcinoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Surgery is considered the main treatment in tongue cancer patients, while patients with advanced stage undergo postoperative radiotherapy and chemotherapy ( 11 , 12 ). Radical resection of tongue cancer causes great trauma to the patients and changes the normal anatomical structure and reduces the quality of life of the patients.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound-guided microwave ablation in the treatment of early-stage tongue cancer

Yang

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTongue cancer is a common malignant tumor of the head and neck. Its treatment methods include surgery, radiotherapy, and chemotherapy. However, these treatments have serious side effects and poor cosmetic effect, so it is urgent to find new treatment methods. We pioneered the use of microwave ablation (MWA) in the treatment of early tongue cancer and achieved good results.Case PresentationA 67-year-old woman (Han nationality) was admitted to the hospital because of progressive aggravation of tongue pain. She had a history of tongue pain of more than 1 year. Pathological biopsy showed squamous cell carcinoma; following this, radical operation of the tongue cancer was planned. The preoperative examination showed thyroid occupation in the upper mediastinum region compressing the airway; hence, the risk of general anesthesia was high. Consent was obtained from the patient and her family. Ultrasound-guided MWA was successfully performed under the lingual nerve block. The patient was followed for 1 year. She recovered well with no dysphagia and unclear articulation symptoms, and the cosmetic effect was excellent.ConclusionTo our knowledge, this is the first case of using MWA for the treatment of early-stage tongue cancer (ESTC). Ultrasound-guided MWA may be used for ESTC that can completely ablate the tumor and retain the function of the tongue, further improving the quality of life of the patient. However, it is only a case report and needs more research to verify the use of MWA in ESTC.

show abstract

“…Moreover, the 5-year survival rate of TSCC patients has shown no obvious improvement over the past decades, while the incidence is gradually increasing in young people 3. Despite the great advances in diagnosis and therapy of TSCC,4,5 it is still necessary to clarify the molecular mechanisms underlying TSCC pathogenesis in order to identify more effective interventions.…”

Section: Introductionmentioning

confidence: 99%

lncRNA MALAT1 potentiates the progression of tongue squamous cell carcinoma through regulating miR-140-5p-PAK1 pathway

Zhu

Zhang

Chen

et al. 2019

OTT

View full text Add to dashboard Cite

Background Tongue squamous cell carcinoma (TSCC) is the second most common malignancy in oral carcinoma. lncRNA metastasis-associated lung adenocarcinoma transcript 1 ( MALAT1 ) was regarded as an oncogenic factor in various carcinomas. However, its underlying molecular mechanisms in the development and progression of TSCC have not been well featured till now. Methods The expressions of MALAT1 , miR-140-5p and p21 (RAC1)-activated kinase 1 (PAK1) mRNA were measured by RT-qPCR assay. The protein level of PAK1 was determined by western blot analysis. Cell viability was detected by Cell Counting Kit-8 assay. Transwell chamber was used to detect cell migratory and invasive capability. Luciferase reporter assay, RNA-binding protein immunoprecipitation (RIP) assay and biotin pull-down assay were applied to evaluate the relationship between MALAT1 , miR-140-5p and PAK1. Xenograft experiments were performed to assess the effect and mechanism of MALAT1 in TSCC tumor growth. Results The expression of MALAT1 and p21 (RAC1)-activated kinase 1 (PAK1) was upregulated and microRNA-140-5p ( miR-140-5p ) expression was downregulated in TSCC tissues and cells. MALAT1 knockdown induced miR-140-5p expression by direct interaction. Moreover, MALAT1 knockdown inhibited proliferation, migration, and invasion by upregulating miR-140-5p expression in TSCC cells. Additionally, PAK1 was identified as a direct target of miR-140-5p . Also, MALAT1 knockdown inhibited PAK1 expression by upregulating miR-140-5p in TSCC cells. Furthermore, miR-140-5p overexpression curbed the proliferation, migration, and invasion of TSCC cells by targeting PAK1. Finally, MALAT1 knockdown inhibited tumor growth by upregulating miR-140-5p and downregulating PAK1 in mouse xenograft models of TSCC. Conclusion MALAT1 contributed to TSCC progression via miR-140-5p -PAK1 regulatory axis, highlighting a potential target for TSCC management.

show abstract

Radiotherapy alone or combined with chemotherapy for base of tongue squamous cell carcinoma

Abstract: 4. Laryngoscope, 127:1589-1594, 2017.

Cited by 6 publications

References 43 publications

Radiation treatment of soft palate squamous cell carcinoma

Radiation treatment of soft palate squamous cell carcinoma

Ultrasound-guided microwave ablation in the treatment of early-stage tongue cancer

<p>lncRNA <em>MALAT1</em> potentiates the progression of tongue squamous cell carcinoma through regulating <em>miR-140-5p</em>-PAK1 pathway</p>

Contact Info

Product

Resources

About